These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 21439785)

  • 1. Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity.
    Baugh M; Black D; Westwood P; Kinghorn E; McGregor K; Bruin J; Hamilton W; Dempster M; Claxton C; Cai J; Bennett J; Long C; McKinnon H; Vink P; den Hoed L; Gorecka M; Vora K; Grant E; Percival MD; Boots AM; van Lierop MJ
    J Autoimmun; 2011 May; 36(3-4):201-9. PubMed ID: 21439785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor.
    Podolin PL; Bolognese BJ; Carpenter DC; Davis TG; Johanson RA; Fox JH; Long E; Dong X; Marquis RW; Locastro SM; Terfloth GJ; Kurali E; Peterson JJ; Smith BR; McQueney MS; Yamashita DS; Capper-Spudich EA
    J Immunol; 2008 Jun; 180(12):7989-8003. PubMed ID: 18523262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate ameliorates T cell dependent autoimmune arthritis and encephalomyelitis but not antibody induced or fibroblast induced arthritis.
    Lange F; Bajtner E; Rintisch C; Nandakumar KS; Sack U; Holmdahl R
    Ann Rheum Dis; 2005 Apr; 64(4):599-605. PubMed ID: 15345503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.
    Asagiri M; Hirai T; Kunigami T; Kamano S; Gober HJ; Okamoto K; Nishikawa K; Latz E; Golenbock DT; Aoki K; Ohya K; Imai Y; Morishita Y; Miyazono K; Kato S; Saftig P; Takayanagi H
    Science; 2008 Feb; 319(5863):624-7. PubMed ID: 18239127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.
    Fridman JS; Scherle PA; Collins R; Burn TC; Li Y; Li J; Covington MB; Thomas B; Collier P; Favata MF; Wen X; Shi J; McGee R; Haley PJ; Shepard S; Rodgers JD; Yeleswaram S; Hollis G; Newton RC; Metcalf B; Friedman SM; Vaddi K
    J Immunol; 2010 May; 184(9):5298-307. PubMed ID: 20363976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: clinical and immunological studies.
    Teitelbaum D; Aharoni R; Klinger E; Kreitman R; Raymond E; Malley A; Shofti R; Sela M; Arnon R
    Ann N Y Acad Sci; 2004 Dec; 1029():239-49. PubMed ID: 15681762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion in vivo from an early dominant Th0/Th1 response to a Th2 phenotype during the development of collagen-induced arthritis.
    Doncarli A; Stasiuk LM; Fournier C; Abehsira-Amar O
    Eur J Immunol; 1997 Jun; 27(6):1451-8. PubMed ID: 9209498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.
    Svelander L; Erlandsson-Harris H; Astner L; Grabowska U; Klareskog L; Lindstrom E; Hewitt E
    Eur J Pharmacol; 2009 Jun; 613(1-3):155-62. PubMed ID: 19358841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation.
    Fu YF; Zhu YN; Ni J; Zhong XG; Tang W; Re YD; Shi LP; Wan J; Yang YF; Yuan C; Nan FJ; Lawson BR; Zuo JP
    J Pharmacol Exp Ther; 2006 Nov; 319(2):799-808. PubMed ID: 16914558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of PEGylated TNFR1-selective antagonistic mutant TNF in experimental autoimmune encephalomyelitis mice.
    Nomura T; Abe Y; Kamada H; Shibata H; Kayamuro H; Inoue M; Kawara T; Arita S; Furuya T; Yamashita T; Nagano K; Yoshikawa T; Yoshioka Y; Mukai Y; Nakagawa S; Taniai M; Ohta T; Serada S; Naka T; Tsunoda S; Tsutsumi Y
    J Control Release; 2011 Jan; 149(1):8-14. PubMed ID: 20036293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoimmune inflammation from the Th17 perspective.
    Furuzawa-Carballeda J; Vargas-Rojas MI; Cabral AR
    Autoimmun Rev; 2007 Jan; 6(3):169-75. PubMed ID: 17289553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IgD antibody attenuates collagen-induced arthritis by selectively depleting mature B-cells and promoting immune tolerance.
    Nguyen TG; Little CB; Yenson VM; Jackson CJ; McCracken SA; Warning J; Stevens V; Gallery EG; Morris JM
    J Autoimmun; 2010 Aug; 35(1):86-97. PubMed ID: 20456921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis.
    Seki M; Oomizu S; Sakata KM; Sakata A; Arikawa T; Watanabe K; Ito K; Takeshita K; Niki T; Saita N; Nishi N; Yamauchi A; Katoh S; Matsukawa A; Kuchroo V; Hirashima M
    Clin Immunol; 2008 Apr; 127(1):78-88. PubMed ID: 18282810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model.
    Jung EJ; Hur M; Kim YL; Lee GH; Kim J; Kim I; Lee M; Han HK; Kim MS; Hwang S; Kim S; Woo AM; Yoon Y; Park HJ; Won J
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1005-13. PubMed ID: 19741152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of IL-4 in regulation of murine collagen-induced arthritis.
    Myers LK; Tang B; Stuart JM; Kang AH
    Clin Immunol; 2002 Feb; 102(2):185-91. PubMed ID: 11846461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis.
    Murakami Y; Akahoshi T; Aoki N; Toyomoto M; Miyasaka N; Kohsaka H
    Arthritis Rheum; 2009 Jun; 60(6):1615-23. PubMed ID: 19479878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.